RxDoctor Payments Data

Thiruvengadam Kulasekaran

Neurology with Special Qualifications in Child Neurology · Akron, OHNPI 1013991843

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $2,400 of the $3,795 with a category attached, or 63.2%. Supernus Pharmaceuticals, Inc. accounts for 81.5% of it on its own, with 15 other manufacturers making up the rest. Reporting peaked in 2021 at $2,803 and has fallen 93.2% since, to $191 in 2022.

$3,795in general payments, 2019–2025

Across 112 payments — averaging $33.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Supernus Pharmaceuticals, Inc.$3K
  • Greenwich Biosciences, Inc.$140
  • Amgen$97
  • Ironshore Pharmaceuticals Inc.$66
  • Takeda Pharmaceuticals U.S.A., Inc.$64
  • Corium, LLC$62
  • plus $272 from 10 others

What the payments were for

  • Speaking & faculty fees$2,40063%
  • Food & beverage$1,36636%
  • Education$291%

General payments by program year

19
20
21
22

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,795 in reported general payments places this provider in the 65th percentile of 113 neurology with special qualifications in child neurology providers in Ohio.

See all neurology with special qualifications in child neurology providers in Ohio

Other neurology with special qualifications in child neurology in Akron

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →